2Owens R C, Ambrose J P G, Nihgtingale C H. Antibiotic optimization-concepts and strategies in clinical practice [ M ]. New York: Marecl Dekker, 2005:89
3Smith A L, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis [J]. J Pediatr, 1999,134(4): 413
4Wu Y L, Scott E M, Po A L, et al. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa[ J ]. J Antimicrob Chemother, 1999,44(3): 389
5Bakri F E, Pallett A, Smith A G, et al. Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy[J]. J Antimicrob Chemother, 2000, 45(3): 383
6Hernandez M E, Ramos M J, Ferrer N F. Azlocillin plus amikacin: an alternative therapy for sepsis caused by resistant Staphylococci[J]. Rev Panam Salud Publica, 2004, 16(5 ): 315
7Hujer A M, Kania M, Gerken T, et al. Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBPS, a type Ⅱ bacterial transpeptidase [ J ]. Antimicrob Agents Chemother, 2005, 49 (2) : 612
8Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units) [J]. Antimicrob Agents Chemother, 2002, 46(8):2327
